Trust Company of Vermont’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $27K | Sell |
35
-415
| -92% | -$282K | ﹤0.01% | 688 |
|
|
2025
Q3 | $253K | Sell |
450
-20
| -4% | -$11.3K | 0.01% | 325 |
|
|
2025
Q2 | $247K | Hold |
470
| – | – | 0.01% | 318 |
|
|
2025
Q1 | $298K | Hold |
470
| – | – | 0.01% | 293 |
|
|
2024
Q4 | $335K | Buy |
470
+313
| +199% | +$263K | 0.02% | 291 |
|
|
2024
Q3 | $165K | Buy |
157
+12
| +8% | +$13.4K | 0.01% | 355 |
|
|
2024
Q2 | $152K | Buy |
145
+123
| +559% | +$119K | 0.01% | 350 |
|
|
2024
Q1 | $21.2K | Buy |
22
+20
| +1,000% | +$19K | ﹤0.01% | 615 |
|
|
2023
Q4 | $1.76K | Sell |
2
-20
| -91% | -$16.5K | ﹤0.01% | 703 |
|
|
2023
Q3 | $18.1K | Hold |
22
| – | – | ﹤0.01% | 586 |
|
|
2023
Q2 | $15.8K | Sell |
22
-2
| -8% | -$1.54K | ﹤0.01% | 616 |
|
|
2023
Q1 | $19.7K | Buy |
24
+2
| +9% | +$1.51K | ﹤0.01% | 603 |
|
|
2022
Q4 | $15.9K | Hold |
22
| – | – | ﹤0.01% | 610 |
|
|
2022
Q3 | $15K | Hold |
22
| – | – | ﹤0.01% | 646 |
|
|
2022
Q2 | $13K | Buy |
+22
| New | +$14.3K | ﹤0.01% | 649 |
|
|
2022
Q1 | – | Sell |
-24
| Closed | -$16K | – | 644 |
|
|
2021
Q4 | $16K | Buy |
+24
| New | +$14.8K | ﹤0.01% | 612 |
|
|
2021
Q3 | – | Sell |
-24
| Closed | -$13K | – | 616 |
|
|
2021
Q2 | $13K | Buy |
24
+4
| +20% | +$2.03K | ﹤0.01% | 619 |
|
|
2021
Q1 | $9K | Sell |
20
-5
| -20% | -$2.43K | ﹤0.01% | 643 |
|
|
2020
Q4 | $12K | Hold |
25
| – | – | ﹤0.01% | 609 |
|
|
2020
Q3 | $14K | Hold |
25
| – | – | ﹤0.01% | 570 |
|
|
2020
Q2 | $15K | Buy |
25
+5
| +25% | +$2.84K | ﹤0.01% | 574 |
|
|
2020
Q1 | $10K | Sell |
20
-15
| -43% | -$6.19K | ﹤0.01% | 660 |
|
|
2019
Q4 | $14K | Hold |
35
| – | – | ﹤0.01% | 668 |
|
|
2019
Q3 | $10K | Buy |
35
+15
| +75% | +$4.44K | ﹤0.01% | 747 |
|
|
2019
Q2 | $6K | Hold |
20
| – | – | ﹤0.01% | 819 |
|
|
2019
Q1 | $8K | Sell |
20
-20
| -50% | -$8.24K | ﹤0.01% | 747 |
|
|
2018
Q4 | $14K | Sell |
40
-50
| -56% | -$18.3K | ﹤0.01% | 681 |
|
|
2018
Q3 | $36K | Hold |
90
| – | – | ﹤0.01% | 570 |
|
|
2018
Q2 | $31K | Buy |
90
+66
| +275% | +$20.6K | ﹤0.01% | 610 |
|
|
2018
Q1 | $8K | Hold |
24
| – | – | ﹤0.01% | 782 |
|
|
2017
Q4 | $10K | Hold |
24
| – | – | ﹤0.01% | 762 |
|
|
2017
Q3 | $11K | Sell |
24
-3
| -11% | -$1.43K | ﹤0.01% | 723 |
|
|
2017
Q2 | $13K | Buy |
27
+3
| +13% | +$1.31K | ﹤0.01% | 703 |
|
|
2017
Q1 | $10K | Hold |
24
| – | – | ﹤0.01% | 711 |
|
|
2016
Q4 | $8K | Buy |
+24
| New | +$9.13K | ﹤0.01% | 731 |
|
Other funds holding REGN
N
Trust Company of Vermont's REGN Position: Q4 2025 in Review
Trust Company of Vermont reduced its Regeneron Pharmaceuticals (REGN) stake by 92% in Q4 2025, selling an estimated $282K and leaving 35 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #688.
Trust Company of Vermont first reported a position in REGN in Q4 2016 and has held it in 35 quarters since. The position peaked at $335K in Q4 2024. 1,386 funds tracked by Wall St. Rank hold REGN as of Q4 2025.
- Trust Company of Vermont held 35 shares of Regeneron Pharmaceuticals worth $27K as of Q4 2025.
- Trust Company of Vermont sold 415 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $282K.
- Regeneron Pharmaceuticals made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #688 holding.
- Trust Company of Vermont first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 35 quarters since.
- Trust Company of Vermont's Regeneron Pharmaceuticals position peaked at $335K in Q4 2024.
- 1,386 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.
Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.